Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab + oxaliplatin is a combination regimen used primarily in the treatment of metastatic colorectal cancer. Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to and neutralizes vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and reducing tumor vascularization. Oxaliplatin is a platinum-based alkylating agent that interferes with DNA replication, leading to cell death. This combination is often administered with other agents such as fluoropyrimidines (e.g., capecitabine or 5-fluorouracil) for enhanced efficacy in colorectal cancer therapy[1][2][3][4][5][6][8].
- Other names
- none
02
Targets
Beyond the preview
Go deeper on bevacizumab + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + oxaliplatin.